In this article, recent progress in cardiotoxicity testing based on the use of immortalized cell lines or human embryonic stem cell (hESC) derived cardiomyocytes in combination with state‐of‐the‐art bioanalytical methods and sensors is reviewed. The focus is on hESC‐derived cells and their refinement into competent testing cells, but the access and utility of other relevant cell types are also discussed. Recent developments in sensor techniques and bioanalytical approaches for measuring critical cardiotoxicity parameters are highlighted, together with aspects of data evaluation and validation. Finally, recommendations for further research are given.
MANDENIUS Carl-Frederik;
STEEL Daniela;
NOOR Fozia;
MEYER Thomas;
HEINZELE Elmar;
ASP Julia;
ARAIN Sarina;
KRAUSHAAR Udo;
BREMER Susanne;
CLASS Reiner;
SARTIPY Peter;
2018-03-19
JOHN WILEY & SONS LTD
JRC62288
0260-437X,
http://onlinelibrary.wiley.com/doi/10.1002/jat.1663/abstract,
https://publications.jrc.ec.europa.eu/repository/handle/JRC62288,
10.1002/jat.1663,
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Additional supporting files
| File name | Description | File type | |
|---|
